Elevate Your Toxicity Assays: New Models with Biological Relevance and PredictabilityApr 08, 2021 at 12:00 PM ET
Designing cell-based toxicity assays can be challenging; large numbers of cells are needed to satisfy the throughput of the assay, yet the cells must be physiologically relevant for the assay to be predictive. While primary cells exhibit the highest biological relevance, hTERT-immortalized primary cells exhibit the growth characteristics of continuous cell lines with physiological attributes of primary cells. In this webinar ATCC scientists discuss the characteristics and utility of various respiratory, skin, and kidney models in toxicological assays. Additionally, the speakers present data that demonstrates that these modified primary cells are effective tools that provide tissue-relevant results and reproducibility for any cell-based assay, including toxicology assays.
- hTERT-immortalized primary cells are comparable to primary cells regarding physiological relevance, but are able to avoid replicative senescence
- Using well-characterized hTERT-immortalized cells, ATCC has created credible cell models for toxicological studies on the kidney, skin, and airway
- Our data show that these modified primary cells are effective tools that provide tissue-relevant results and reproducibility for any cell-based assay, including toxicology assays
Watch the Presentation
Kevin Grady, BS
Senior Product Line Business Manager, ATCC
Kevin Grady is the Senior Product Line Business Manager for Cell Biology at ATCC. He has been with ATCC for 8 years; prior to ATCC, he held positions at Lonza as Worldwide Product Manager and Director of Scientific Support. Kevin has a long history in the life science industry additionally serving as Director of Scientific Support at Amaxa and Manager of Technical Support at Life Technologies. Mr. Grady has always found great satisfaction in helping researchers learn how to use available products and tools to be more productive and successful in reaching their research goals.
Kevin Tyo, PhD
Dr. Kevin Tyo is a Scientist in Research and Development at ATCC. Dr. Tyo has over 10 years of experience in biological research. In his current role, Dr. Tyo develops and evaluates advanced in vitro co-culture models, as well as conducts toxicological testing. Dr. Tyo received his Ph.D. in Pharmacology and Toxicology from the University of Louisville in 2019, where he designed and tested topical drug delivery platforms that provided sustained release of antiviral therapeutics.